BASH ALAN
Known title: Interim CEOCIK: 0001908421
Associated companies
Transaction History
| LEGN | ▲ Buy | Grant | 4,908 | $0 | 8/14/2026 | View on chart |
| LEGN | ▲ Buy | Grant | 4,908 | $0 | 8/14/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Legend Biotech Faces Revised Valuation After CARVYKTI Data
Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.
Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.